Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...
Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
FiercePharma3d
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics today
EST Cathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics (BEAM) todayDiscover the Best Stocks and Maximize Your Portfolio: ...
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...
ETF Daily News20d
Beam Therapeutics (NASDAQ:BEAM) Given Buy Rating at HC Wainwright
NASDAQ BEAM opened at $25.59 on Monday. Beam Therapeutics has a 52 week low of $20.84 and a 52 week high of $49.50. The business’s fifty day simple moving average is $26.50 and its 200-day ...